SPAPJ696.02 Antibody

Contextual Analysis of Antibody Naming Conventions

Antibody identifiers typically follow standardized formats reflecting either:

• Target specificity (e.g., anti-BRAF V600E [RM8] )

• Research project codes (e.g., Abs-9 against S. aureus SpA5 )

• Database accession numbers (e.g., SAbDab entries tracking structural features )

The "SPAPJ696.02" format does not align with established naming systems in major antibody databases:

High-Throughput Antibody Discovery (Exemplar: Abs-9 Antibody2)

Diagnostic Antibody Development Pathways

The evaluation of Schistosoma japonicum antigens demonstrates rigorous validation workflows applicable to novel antibodies :

Key Validation Stages

1. Target Expression Profiling

   • Temporal expression analysis (e.g., SjSP-216 in juvenile worms)

2. Serological Sensitivity

   Antigen	Seroconversion Time (Weeks)	Sensitivity (%)
   SjSP-13	3	100
   SjSP-216	3	100

3. Cross-Reactivity Testing

   • Protein microarrays with 196 antigens

Recommendations for Further Investigation

1. Database Queries

   • Structural Antibody Database (SAbDab): Filter using advanced sequence/structure parameters

   • AbDb: Search redundancy-filtered datasets

2. Commercial Reagent Verification

   • Contact major antibody vendors (e.g., RevMAb ) for catalog matches

3. Nomenclature Clarification

   • Confirm identifier format with originating institution/lab